List of Excipients in Branded Drug PROGRAF

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	PROGRAF	tacrolimus	21695-170	CROSCARMELLOSE SODIUM
Rebel Distributors Corp	PROGRAF	tacrolimus	21695-170	GELATIN
Rebel Distributors Corp	PROGRAF	tacrolimus	21695-170	HYPROMELLOSES
Rebel Distributors Corp	PROGRAF	tacrolimus	21695-170	LACTOSE MONOHYDRATE
Rebel Distributors Corp	PROGRAF	tacrolimus	21695-170	MAGNESIUM STEARATE

PROGRAF Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

PROGRAF is an immediate-release tacrolimus product whose commercial value depends on narrow therapeutic index control, consistent absorption, capsule integrity, and reliable supply. Its excipient strategy creates opportunities in generic differentiation, pediatric delivery, tacrolimus modified release, intravenous formulation reformulation, and specialty pharmacy support. The largest commercial risks are generic price erosion, therapeutic substitution, pharmacokinetic variability, and the limited ability to change excipients without affecting bioequivalence.

What excipients are used in PROGRAF capsules and injection?

PROGRAF uses different excipient systems for oral capsules and intravenous injection. The oral product is a solid dosage form containing tacrolimus, while the injection relies on a solubilizing vehicle because tacrolimus has very low aqueous solubility.

PROGRAF presentation	Key excipient functions	Commercial relevance
0.5 mg, 1 mg and 5 mg capsules	Fillers, binders, disintegrants, lubricants and capsule-shell colorants	Generic substitution, allergen control, capsule appearance and manufacturing cost
Intravenous injection	Polyoxyl 60 hydrogenated castor oil and dehydrated alcohol vehicle	Hypersensitivity risk, infusion handling, alcohol exposure and reformulation opportunity
Oral capsule shell	Gelatin and colorant system	Vegetarian, religious, allergen and supply-chain differentiation
Tacrolimus drug product generally	Excipients supporting dissolution and dose uniformity	Bioequivalence, therapeutic drug monitoring and product-switching risk

The U.S. prescribing information identifies lactose, hypromellose, croscarmellose sodium, magnesium stearate and titanium dioxide among the oral capsule ingredients. Capsule-shell colorants vary by strength and may include iron oxides or other approved colorants. The injection formulation contains polyoxyl 60 hydrogenated castor oil and dehydrated alcohol as critical vehicle components (Astellas Pharma US, Inc., 2024; U.S. National Library of Medicine, n.d.).

The exact excipient composition should be taken from the approved package insert for the target market. Tacrolimus products are not compositionally identical across jurisdictions, strengths or manufacturers.

How does the PROGRAF excipient system affect product performance?

The excipient system affects dissolution, dose uniformity, mechanical processing, capsule stability and the extent to which patients can switch between products without clinically meaningful changes in tacrolimus exposure.

Lactose and capsule fill performance

Lactose can act as a diluent and improve powder handling. Its commercial drawbacks include suitability concerns for patients with lactose intolerance, although the amount in a capsule may not produce symptoms in most patients. Lactose also creates a potential differentiation point for products marketed to hospitals, transplant centers or pharmacies seeking alternative excipient profiles.

Hypromellose and croscarmellose sodium

Hypromellose can support powder binding and capsule-fill uniformity. Croscarmellose sodium promotes rapid liquid uptake and capsule disintegration. Changes to either excipient may alter dissolution behavior, particularly where tacrolimus particle size, polymorphic form or drug loading also changes.

For a narrow therapeutic index drug, excipient changes require tighter development controls than ordinary immediate-release generics. Dissolution similarity alone may not establish commercial interchangeability. The sponsor must demonstrate bioequivalence under the applicable FDA pathway, commonly an abbreviated new drug application for a generic product.

Magnesium stearate

Magnesium stearate improves powder flow and reduces adhesion during capsule manufacture. Excessive lubrication or prolonged blending can reduce wettability and slow dissolution. This makes lubricant concentration and blending time relevant to process development, even when magnesium stearate is present in a conventional amount.

Polyoxyl 60 hydrogenated castor oil in injection

The intravenous product uses a nonaqueous vehicle to solubilize tacrolimus. Polyoxyl 60 hydrogenated castor oil has been associated with hypersensitivity reactions in injectable drug products, while the alcohol component creates handling and patient-exposure considerations. The label requires dilution before infusion and includes warnings relating to anaphylaxis and anaphylactoid reactions (Astellas Pharma US, Inc., 2024).

This excipient system is a clear target for reformulation. Potential platforms include lipid emulsions, cyclodextrin complexes, nanosuspensions, polymeric micelles and other solubilizing systems. Each platform would face substantial development requirements because the reformulated product would need to demonstrate comparable exposure, infusion compatibility, safety and stability.

What excipient patents protect PROGRAF?

The core commercial protection for PROGRAF has historically come from tacrolimus composition, formulation and use patents rather than from a large standalone excipient patent estate. The principal U.S. composition-of-matter and product exclusivity periods have expired, and FDA-approved generic tacrolimus products are available.

A commercially relevant excipient patent would need to claim more than the presence of a routine ingredient. Stronger claim types could cover:

• A specific tacrolimus-to-excipient ratio.
• A defined dissolution profile.
• A particle-size distribution combined with a selected carrier.
• A stabilized injectable solution or emulsion.
• A low-alcohol or alcohol-free intravenous vehicle.
• A capsule composition that reduces food-effect variability.
• A pediatric granule, suspension or orally dispersible formulation.
• A manufacturing process that controls tacrolimus degradation or agglomeration.

Routine use of lactose, hypromellose, croscarmellose sodium or magnesium stearate is unlikely to create a durable blocking position without a technical effect and narrow composition or process limitations. Patentability and enforceability would depend on the full specification, prior art, enablement, written description and infringement evidence.

When did PROGRAF lose exclusivity?

PROGRAF has lost its principal small-molecule exclusivity barriers in the United States. Tacrolimus immediate-release capsules have generic competition, and FDA-listed products include multiple strengths and manufacturers (U.S. Food and Drug Administration, n.d.-a).

The commercial exclusivity timeline is best analyzed in separate layers:

Exclusivity layer	Status
Tacrolimus active ingredient	Expired in the United States
Original immediate-release capsule protection	Expired or no longer blocks routine generic entry
FDA small-molecule regulatory exclusivity	Expired for the original product
Formulation-specific protection	Must be assessed patent by patent and jurisdiction by jurisdiction
Brand distribution and transplant-center relationships	Commercial rather than statutory exclusivity
New delivery systems	Potentially protectable through new patents and regulatory applications

PROGRAF’s loss of exclusivity does not eliminate commercial value. Transplant products can retain brand demand because physicians and pharmacists prioritize product consistency, patient monitoring and continuity of therapy. That residual value is vulnerable to payer substitution and generic procurement policies.

What is the FDA regulatory status of PROGRAF and its generic products?

PROGRAF is FDA-approved as an immunosuppressant for prevention of organ rejection in kidney, liver and heart transplant recipients. It is available in oral capsules and intravenous form. Tacrolimus requires therapeutic drug monitoring because exposure varies across patients and because underexposure can increase rejection risk while overexposure can increase toxicity (Astellas Pharma US, Inc., 2024).

FDA-approved generic tacrolimus capsules are generally approved through ANDAs. Generic sponsors must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. They do not need to repeat the full clinical efficacy program conducted for the innovator product.

The regulatory significance of excipients is higher for tacrolimus than for many conventional products because:

1. Small exposure differences can affect clinical management.
2. Patients may be switched between products in routine pharmacy practice.
3. Food, gastrointestinal function, interacting drugs and formulation attributes can alter exposure.
4. Transplant patients may require repeat blood-level testing after a product change.

The FDA has warned that tacrolimus products should not be substituted without appropriate prescriber and monitoring controls in certain clinical settings. Product-specific substitution rules also depend on state law, payer policy and pharmacy practice.

What formulations are protected by tacrolimus excipient strategy?

The strongest commercial opportunities are outside the conventional immediate-release capsule.

Pediatric granules and oral suspensions

Children may have difficulty swallowing capsules, and pediatric dosing frequently requires weight-based adjustments. A granule or oral suspension product could improve administration and dose flexibility.

Key excipient requirements include:

• Taste masking without compromising dissolution.
• Uniform dose delivery at low strengths.
• Physical and chemical suspension stability.
• Resistance to settling and aggregation.
• Dosing-device compatibility.
• Preservative selection.
• Low-volume administration.
• Acceptable storage after reconstitution.

A pediatric formulation could support a new patent family if it combines a defined particle engineering method, excipient system, dosing accuracy and stability profile. The principal regulatory risk is that a new formulation may not qualify as a simple generic of the capsule and could require a more extensive application.

Modified-release tacrolimus

Modified-release tacrolimus products seek once-daily administration and potentially improved adherence. They use polymers, coating systems, matrix formers or multiparticulate technologies to control release.

The commercial opportunity is substantial because adherence is a major transplant-management issue. The competitive barrier is also high. A modified-release product must demonstrate comparable clinical control despite a different concentration-time profile. Bioequivalence may require multiple studies, and conversion from immediate-release tacrolimus must be supported by dosing guidance and therapeutic drug monitoring.

Alcohol-free intravenous tacrolimus

An alcohol-free injectable product could target patients with sensitivity to ethanol, critical-care use, pediatric transplantation and hospital systems seeking simplified infusion handling. Candidate technologies include aqueous colloidal systems, lipid emulsions, cyclodextrins and surfactant-based formulations.

The principal technical risks are precipitation after dilution, adsorption to infusion materials, particulate formation, infusion-site reactions and preservation of tacrolimus potency during storage.

Excipient-minimized capsules

A capsule that removes lactose, gelatin, titanium dioxide or selected colorants could address specific market segments. This strategy is more likely to support commercial differentiation than broad patent protection unless the excipient change produces a measurable performance advantage.

Potential positioning includes:

• Lactose-free supply.
• Gelatin-free or vegetarian capsules.
• Reduced-colorant products.
• Products suitable for specific religious or dietary requirements.
• Improved supply continuity during excipient shortages.

How strong is the PROGRAF patent estate?

The original PROGRAF patent estate is commercially weak as a barrier to immediate-release generic capsules because generic tacrolimus products are already marketed. The stronger strategic assets are clinical familiarity, transplant-center experience, manufacturing controls, pharmacovigilance data and physician confidence.

Estate component	Relative strength for blocking generic capsules	Commercial assessment
Tacrolimus active ingredient	Low	Expired core protection
Conventional capsule excipients	Low	Generally routine and design-aroundable
Immediate-release capsule formulation	Low to moderate	Depends on surviving claims and jurisdiction
Modified-release delivery	Moderate to strong	Potentially valuable if clinically differentiated
Pediatric delivery	Moderate	Opportunity depends on formulation and regulatory pathway
Intravenous reformulation	Moderate to strong	Technical barrier is meaningful, but development cost is high
Manufacturing process controls	Moderate	Can protect quality and supply, but may be difficult to enforce
Brand and clinical switching controls	Moderate commercially	Important despite limited patent exclusivity

A new excipient patent would have the greatest value where it controls a clinically meaningful attribute that competitors cannot easily reproduce. Examples include stable low-dose delivery, reduced pharmacokinetic variability, improved suspension dosing or a safer injectable vehicle.

Which companies are challenging PROGRAF commercially?

Generic tacrolimus competition comes from multiple manufacturers operating through ANDA approvals and pharmacy channels. The competitive field includes large generic companies and regional suppliers, with product availability varying by strength, wholesaler and procurement contract.

The main competitive groups are:

• Large multinational generic manufacturers.
• Specialty transplant-focused suppliers.
• Contract manufacturers with tacrolimus production capability.
• Developers of once-daily tacrolimus products.
• Hospital suppliers competing on injectable availability and price.

The primary competitive variables are price, supply reliability, FDA compliance, dosage-form breadth, authorized-generic arrangements, pharmacy substitution and willingness to support transplant-center switching protocols.

A biosimilar strategy is not relevant to PROGRAF because tacrolimus is a small-molecule drug, not a biologic. The relevant pathway is generic substitution, not biosimilar approval under the Public Health Service Act.

What patent litigation and Paragraph IV risks affect PROGRAF?

Generic tacrolimus capsules entered after the expiration of the core barriers, so current litigation risk is more likely to involve:

• Later-developed modified-release formulations.
• Pediatric dosage forms.
• Injectable reformulations.
• Manufacturing processes.
• Specific methods of managing transplant patients.
• Distribution agreements and supply arrangements.

For a new tacrolimus product, a Paragraph IV certification could challenge listed patents in the Orange Book. The sponsor would need to evaluate whether the patent claims cover the proposed formulation, method of use, strength, dosage form or manufacturing process. A Paragraph IV notice can lead to patent litigation and a 30-month stay of FDA approval under applicable statutory conditions, although the commercial effect depends on the listed patent and litigation posture (U.S. Food and Drug Administration, n.d.-b).

The Orange Book should be reviewed by active ingredient, dosage form and strength. Patent listings can change as products, patents and regulatory certifications change. A product-by-product review is required before making a launch or freedom-to-operate decision.

What licensing deals could create value around PROGRAF excipients?

Licensing opportunities are most credible in delivery technologies rather than commodity excipients. Potential deal structures include:

Opportunity	Likely partner	Value proposition
Alcohol-free injectable tacrolimus	Drug-delivery platform company	Differentiated hospital formulation
Pediatric granules or suspension	Specialty pharma company	Improved administration and lifecycle extension
Modified-release tacrolimus	Transplant-focused company	Once-daily dosing and adherence positioning
Capsule-shell redesign	Capsule manufacturer	Gelatin-free, colorant-reduced or supply-secure product
Tacrolimus particle engineering	CDMO or formulation specialist	Improved dissolution and manufacturing consistency
Excipient supply agreement	Global excipient producer	Dual sourcing and shortage mitigation

Licensing economics would depend on patent term, clinical differentiation, regulatory pathway, manufacturing scale and whether the technology can be used with other poorly soluble drugs. A platform that applies only to tacrolimus may command less value than a platform with a broader immunosuppressant portfolio.

What generic entry risks exist for a PROGRAF reformulation?

A reformulated product can face four separate entry risks.

First, generic manufacturers may replicate the formulation if the excipient system is conventional or disclosed in the public record. Second, competitors may use a different formulation to achieve the same performance, reducing the value of narrow composition claims. Third, payers may treat the reformulation as therapeutically interchangeable with lower-cost immediate-release tacrolimus. Fourth, prescribers may resist conversion because of the need for post-switch blood-level monitoring.

The most defensible commercial position combines:

• A clinically measurable advantage.
• A difficult-to-design-around excipient system.
• A patent covering composition and manufacturing.
• A regulatory pathway that supports market differentiation.
• Transplant-center evidence showing stable exposure or improved adherence.
• Reliable supply at a cost that supports payer adoption.

How does PROGRAF compare with competing tacrolimus products?

Product category	Main advantage	Main excipient opportunity	Main risk
Immediate-release PROGRAF capsules	Established clinical use and broad familiarity	Excipient simplification and supply reliability	Generic price erosion
Generic immediate-release tacrolimus	Low acquisition cost	Cost-efficient, compliant formulation	Switching and supply variability
Once-daily tacrolimus	Adherence and simplified dosing	Modified-release polymers and coatings	Conversion complexity and clinical evidence
Tacrolimus granules or suspension	Pediatric flexibility	Taste masking and dose uniformity	Stability and bioequivalence
Intravenous tacrolimus	Hospital bridge therapy	Alcohol-free and safer solubilization	Infusion compatibility and development cost

What commercial opportunities remain for PROGRAF?

The highest-value opportunities are lifecycle products rather than conventional excipient substitution.

1. A pediatric tacrolimus product with accurate low-dose delivery.
2. An alcohol-free intravenous formulation.
3. A once-daily or otherwise adherence-focused modified-release product.
4. A supply-secure capsule with reduced excipient complexity.
5. A transplant-center switching service supported by therapeutic drug monitoring.
6. A dual-sourced excipient and manufacturing platform for generic suppliers.
7. A formulation platform applicable to tacrolimus and other poorly soluble immunosuppressants.

Revenue exposure is concentrated in the oral transplant market, where generic competition limits price and margin. New delivery systems can preserve higher pricing only if they produce measurable adherence, safety, dosing or hospital-utilization benefits. A simple lactose-free or colorant-free capsule is more likely to compete through procurement and patient preference than through premium pricing.

Key Takeaways

• PROGRAF uses a conventional oral excipient system and a more technically significant injectable vehicle.
• The oral capsule market is exposed to established generic competition.
• Tacrolimus is not subject to biosimilar competition because it is a small molecule.
• Excipient patents on routine ingredients are weak unless linked to a defined technical effect.
• Pediatric, modified-release and alcohol-free injectable products offer the strongest lifecycle opportunities.
• Generic entry risk is highest where a new formulation can be reproduced without difficult manufacturing controls.
• Commercial value depends on clinical evidence, supply reliability, therapeutic drug monitoring and payer acceptance as much as on patent scope.
• The original PROGRAF estate is no longer a strong barrier to immediate-release generic capsules, but new delivery platforms could create protectable follow-on products.

FAQs About PROGRAF Excipients and Commercial Strategy

Does PROGRAF contain lactose?

Yes. U.S. PROGRAF capsules contain lactose among their inactive ingredients, according to the prescribing information.

Can a company launch a lactose-free tacrolimus capsule?

Potentially, but the product would require the applicable FDA generic or reformulation pathway and must meet pharmaceutical-equivalence, bioequivalence, quality and labeling requirements. Removing lactose alone would not necessarily create meaningful patent protection.

Why is intravenous PROGRAF more difficult to reformulate?

Tacrolimus is poorly water-soluble. A replacement vehicle must maintain solubility, stability, infusion compatibility and dose accuracy while limiting hypersensitivity and handling concerns.

Are tacrolimus excipients clinically important during generic substitution?

They can be. Excipients may affect dissolution and absorption, although the approved product must meet bioequivalence requirements. Tacrolimus blood-level monitoring remains important after switching products or changing formulation.

Is once-daily tacrolimus protected mainly by excipients?

Protection usually depends on the complete delivery system, including polymers, coatings, particle engineering, release profile and manufacturing process. A generic excipient list alone is unlikely to capture the full commercial value.

References

1. Astellas Pharma US, Inc. (2024). PROGRAF (tacrolimus) capsules and injection prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. National Library of Medicine. (n.d.). DailyMed: PROGRAF-tacrolimus capsule and injection labeling. https://dailymed.nlm.nih.gov/dailymed/